National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Vismodegib (Erivedge®)

Vismodegib (Erivedge®) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma.

Rapid Review

Commenced Completed Outcome
02/05/13 20/05/13 Full Pharmacoeconomic Evaluation Recommended

Pharmoeconomic Evaluation

Commenced Completed Outcome
16/09/2013  21/01/2014 Reimbursement not recommended


The HSE has approved reimbursement following confidential price negotiations October 2017.